만성 특발성 변비 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Chronic Idiopathic Constipation Treatment Market size is expected to reach USD 7.26 Billion in 2034 from USD 3.89 Billion (2025) growing at a CAGR of 7.17% during 2026-2034.

The chronic idiopathic constipation treatment market is poised for significant growth, driven by the increasing prevalence of gastrointestinal disorders and the rising awareness of available treatment options. Chronic idiopathic constipation (CIC) is a common condition characterized by infrequent bowel movements and difficulty in passing stools, which can significantly impact patients' quality of life. As healthcare providers seek to improve patient outcomes and enhance the management of CIC, the demand for effective therapies, including laxatives, prescription medications, and dietary interventions, is expected to rise, positioning this market for robust expansion.

Moreover, advancements in treatment options for CIC are driving innovation within the market. The development of novel pharmacological agents, such as guanylate cyclase-C agonists and serotonin receptor agonists, has expanded the therapeutic landscape for CIC, offering patients more effective and targeted treatment options. These innovations not only improve bowel function but also address the underlying mechanisms of constipation, enhancing overall patient satisfaction. As research continues to explore new therapies and combination treatments, the chronic idiopathic constipation treatment market is likely to expand further, driven by the promise of improved patient care and quality of life.

Additionally, the growing emphasis on lifestyle modifications and preventive care is shaping the chronic idiopathic constipation treatment landscape. As healthcare providers increasingly recognize the importance of diet, hydration, and physical activity in managing CIC, the demand for educational resources and support programs is likely to increase. This proactive approach not only empowers patients to take control of their condition but also fosters a collaborative relationship between patients and healthcare providers. As the market continues to evolve, the combination of innovative therapies, patient education, and a focus on lifestyle interventions will play a crucial role in driving its future growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Normal-transit constipation
• Slow-transit constipation
• Others

By Therapy Type

• Pharmacological Therapy
• Non-pharmacological Therapy
• ByA Treatment Type
• Medication
• Surgery

By Drugs

• Serotonin-4 (5-Ht4) Receptor Agonist
• Guanylate Cyclase-C Agonist
• Laxatives
• Stimulants
• Others

By Route of Administration

• Oral
• Injectable

By End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others
• ByA Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Others

COMPANIES PROFILED

• ALLERGAN, Mallinckrodt plc, Synergy Pharmaceuticals Inc, Shandong Luoxin Pharmaceutical Group Stock Co Ltd, Takeda Pharmaceutical Company Limited, Sanofi, Zydus Cadila, Boehringer Ingelheim International GmbH, Shreya Life Sciences Pvt Ltd, Abbott, GSK plc, Troikaa Pharmaceuticals Ltd, Lupin, East West Pharma, Ironwood Pharmaceuticals Inc

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Normal-transit constipation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Slow-transit constipation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY THERAPY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Therapy Type
• 5.2. Pharmacological Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Non-pharmacological Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Treatment Type
• 6.2. Medication Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Surgery Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY DRUGS 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Drugs
• 7.2. Serotonin-4 (5-Ht4) Receptor Agonist Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Guanylate Cyclase-C Agonist Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Laxatives Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Stimulants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Route Of Administration
• 8.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY END-USERS 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast End-users
• 9.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 10.1. Market Analysis, Insights and Forecast Distribution Channel
• 10.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 11. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 11.1. Regional Outlook
• 11.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.2.1 By Type
  • 11.2.2 By Therapy Type
  • 11.2.3 By Treatment Type
  • 11.2.4 By Drugs
  • 11.2.5 By Route Of Administration
  • 11.2.6 By End-users
  • 11.2.7 By Distribution Channel
  • 11.2.8 United States
  • 11.2.9 Canada
  • 11.2.10 Mexico
• 11.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.3.1 By Type
  • 11.3.2 By Therapy Type
  • 11.3.3 By Treatment Type
  • 11.3.4 By Drugs
  • 11.3.5 By Route Of Administration
  • 11.3.6 By End-users
  • 11.3.7 By Distribution Channel
  • 11.3.8 United Kingdom
  • 11.3.9 France
  • 11.3.10 Germany
  • 11.3.11 Italy
  • 11.3.12 Russia
  • 11.3.13 Rest Of Europe
• 11.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.4.1 By Type
  • 11.4.2 By Therapy Type
  • 11.4.3 By Treatment Type
  • 11.4.4 By Drugs
  • 11.4.5 By Route Of Administration
  • 11.4.6 By End-users
  • 11.4.7 By Distribution Channel
  • 11.4.8 India
  • 11.4.9 Japan
  • 11.4.10 South Korea
  • 11.4.11 Australia
  • 11.4.12 South East Asia
  • 11.4.13 Rest Of Asia Pacific
• 11.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.5.1 By Type
  • 11.5.2 By Therapy Type
  • 11.5.3 By Treatment Type
  • 11.5.4 By Drugs
  • 11.5.5 By Route Of Administration
  • 11.5.6 By End-users
  • 11.5.7 By Distribution Channel
  • 11.5.8 Brazil
  • 11.5.9 Argentina
  • 11.5.10 Peru
  • 11.5.11 Chile
  • 11.5.12 South East Asia
  • 11.5.13 Rest of Latin America
• 11.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.6.1 By Type
  • 11.6.2 By Therapy Type
  • 11.6.3 By Treatment Type
  • 11.6.4 By Drugs
  • 11.6.5 By Route Of Administration
  • 11.6.6 By End-users
  • 11.6.7 By Distribution Channel
  • 11.6.8 Saudi Arabia
  • 11.6.9 UAE
  • 11.6.10 Israel
  • 11.6.11 South Africa
  • 11.6.12 Rest of the Middle East And Africa

Chapter 12. COMPETITIVE LANDSCAPE

• 12.1. Recent Developments
• 12.2. Company Categorization
• 12.3. Supply Chain & Channel Partners (based on availability)
• 12.4. Market Share & Positioning Analysis (based on availability)
• 12.5. Vendor Landscape (based on availability)
• 12.6. Strategy Mapping

Chapter 13. COMPANY PROFILES OF GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT INDUSTRY

• 13.1. Top Companies Market Share Analysis
• 13.2. Company Profiles
  • 13.2.1 ALLERGAN
  • 13.2.2 Mallinckrodt Plc
  • 13.2.3 Synergy Pharmaceuticals Inc
  • 13.2.4 Shandong Luoxin Pharmaceutical Group Stock Co. Ltd
  • 13.2.5 Takeda Pharmaceutical Company Limited
  • 13.2.6 Sanofi
  • 13.2.7 Zydus Cadila
  • 13.2.8 Boehringer Ingelheim International GmbH
  • 13.2.9 Shreya Life Sciences Pvt Ltd
  • 13.2.10 Abbott
  • 13.2.11 GSK Plc
  • 13.2.12 Troikaa Pharmaceuticals Ltd
  • 13.2.13 Lupin
  • 13.2.14 East West Pharma
  • 13.2.15 Ironwood Pharmaceuticals Inc